Medically reviewed by Benjamin Leach, MD Chronic myelomonocytic leukemia (CMML) is a rare cancer that begins in the ...

therefore lysing the AML blast (blue arrow). This lysis is the definitive goal of an immune therapy for AML by using a defined T-cell epitope peptide derived from a LAA. AML: Acute myeloid ...

Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially ...

The first comprehensive map of the dramatic changes that take place in the blood system over the course of the human lifetime could have implications for the treatment of acute myeloid leukemia and ...

Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) ("Alpha Cognition" [ACI], or the "Company"), a biopharmaceutical company ...

immunosuppressive features facilitate expansion of the dysplastic clone and can eventually lead to disease progression to acute myeloid leukemia. Various cell types contribute to dysregulation of ...

"We ask everyone to get a differential count, which tells you the type of white blood cell blast ... that many times can be the first harbinger. If you see the complete blood cell counts showing ...

The BEXMAB study is a multicenter study, taking place in Finland, UK and the U.S., evaluating the safety and efficacy of bexmarilimab, a novel anti-Clever-1 humanized antibody, with standard of care ...